Pivotal Health
-83%
est. 2Y upside i
Rank
#4030
Sector
Healthcare Data Analytics
Est. Liquidity
~3Y
Data Quality
Data: MediumPivotal Health presents a high-risk equity opportunity due to its recent bankruptcy and reorganization in April 2025, which likely wiped out or severely diluted prior common stock.
Last updated: March 10, 2026
Pivotal Health successfully executes a post-reorganization growth strategy, leveraging its specialized healthcare and real estate data to secure significant new enterprise clients. Revenue grows to $10M+ by 2028, justifying a $45M valuation through a strategic acquisition.
The company stabilizes post-reorganization, maintaining its niche in healthcare data analytics but facing ongoing competitive pressure from incumbents. Revenue remains around $2M-$3M, and the valuation holds at the current estimated $15M, with no clear path to a significant liquidity event within two years.
Dominant incumbents or well-funded competitors expand into Pivotal Health's specialized market, further eroding its market share and pricing power. Growth stalls, leading to another down round or liquidation, wiping out most common stock value, resulting in a valuation of $3M.
Preference Stack Risk
severeThe company's prior $18M in funding likely resulted in a wipeout or severe dilution of common stock during the April 2025 bankruptcy/reorganization. New equity would be subject to the preferences of any post-reorganization funding, which are currently unknown but historically, the funding intensity was very high relative to the estimated current valuation.
Dilution Risk
highGiven the company's recent reorganization and low current revenue, future funding rounds are likely necessary for growth, which would lead to further dilution for existing common shareholders.
Secondary Liquidity
noneAs a small, private company that recently underwent reorganization, there is no active secondary market for its shares.
Questions to Ask at the Interview
Strategic questions based on Pivotal Health's data — designed to show you've done your homework.
- 1
“How has the company's strategic vision and product roadmap been refined since the April 2025 reorganization, particularly in addressing the competitive landscape with larger players like IQVIA and Definitive Healthcare?”
- 2
“Given the current revenue of approximately $2M and the need for growth post-reorganization, what are the specific strategies for customer acquisition and revenue expansion over the next 12-24 months, and how will these initiatives be funded?”
- 3
“Could you provide more detail on the current capital structure post-reorganization, including any new funding rounds, liquidation preferences for preferred shareholders, and a realistic timeline for a liquidity event for common stock holders?”
Community
Valuation Sentiment
Our model estimates -83% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.